• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Zoetis Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation

    8/27/25 4:21:54 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ZTS alert in real time by email
    8-K
    false 0001555280 0001555280 2025-08-27 2025-08-27
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    PURSUANT TO SECTION 13 OR 15(d)

    OF THE SECURITIES EXCHANGE ACT OF 1934

    Date of report (Date of earliest event reported): August 27, 2025

     

     

    Zoetis Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   001-35797   46-0696167

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (I.R.S. Employer

    Identification No.)

     

    10 Sylvan Way, Parsippany, New Jersey   07054
    (Address of principal executive offices)   (Zip Code)

    (973) 822-7000

    (Registrant’s telephone number, including area code)

    Not Applicable

    (Former Name or Former Address, if changed since last report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐

    Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading
    Symbol(s)

     

    Name of each exchange
    on which registered

    Common Stock, par value $0.01 per share   ZTS   New York Stock Exchange

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     
     


    Item 1.01. Entry into a Material Definitive Agreement.

    Revolving Credit Facility

    On August 27, 2025, Zoetis Inc. (the “Company”) entered into a revolving credit agreement (the “Credit Agreement”) with a syndicate of banks, JPMorgan Chase Bank, N.A., as administrative agent, and Barclays Bank PLC, Bank of America, N.A., Citibank, N.A. and MUFG Bank, Ltd., as syndication agents, providing for a five-year $1.25 billion senior unsecured revolving credit facility. The Credit Agreement replaced the Company’s existing revolving credit facility. Subject to certain conditions, the Company will have the right to increase the commitments under the Credit Agreement to up to $1.75 billion. The Credit Agreement is not guaranteed by the Company’s subsidiaries.

    Loans under the Credit Agreement will bear interest, at the Company’s option, at rates equal to either: (a) a base rate or (b) a term SOFR rate, in each case plus an applicable margin. Additionally, the Company will pay a facility fee on the commitments under the Credit Agreement, regardless of whether borrowings are outstanding under the Credit Agreement. The applicable margins and the facility fee are determined based on the public ratings of the Company’s senior unsecured non-credit enhanced long-term debt. Interest on borrowings and the facility fee are generally payable quarterly in arrears; however, for loans bearing interest based on a term SOFR rate with a term shorter than three months, interest is payable at the end of such term.

    The Company may voluntarily prepay loans and/or reduce the commitment under the Credit Agreement, in whole or in part, without penalty or premium, subject to certain minimum amounts and increments and the payment of customary breakage costs. No mandatory prepayment is required under the Credit Agreement.

    The Credit Agreement contains a financial covenant requiring the Company to not exceed a maximum total leverage ratio. In addition, the Credit Agreement contains customary affirmative and negative covenants that, among other things, limit or restrict the Company’s and its subsidiaries’ ability, subject to certain exceptions, to incur liens, merge, consolidate or sell, transfer or lease assets and incur priority indebtedness. The Credit Agreement also contains customary events of default.

    The description of the Credit Agreement contained herein is not intended to be complete and is qualified in its entirety by reference to the full text of the Credit Agreement, a copy of which is attached as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.

    Item 1.02. Termination of a Material Definitive Agreement.

    On August 27, 2025, the Company terminated that certain credit agreement dated as of December 21, 2022, among the Company, the lenders party thereto and JPMorgan Chase Bank, N.A., as administrative agent, (the “Prior Credit Agreement”) and all commitments to extend further credit thereunder were therefore terminated. The Prior Credit Agreement was scheduled to expire in December 2027.

    Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

    The information set forth under Item 1.01 above is incorporated by reference into this Item 2.03.

    Item 9.01. Financial Statements and Exhibits.

    (d) Exhibits

     

    Exhibit No.

      

    Description

    10.1    Revolving Credit Agreement dated as of August 27, 2025, among Zoetis Inc., the lenders party thereto, the issuing banks party thereto and JPMorgan Chase Bank, N.A., as administrative agent
    104    Cover Page Interactive Data File (embedded within the Inline XBRL document)

     


    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

        ZOETIS INC.
    Dated: August 27, 2025     By:  

    /s/ Roxanne Lagano

          Roxanne Lagano
          Executive Vice President,
          General Counsel and Corporate Secretary
    Get the next $ZTS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ZTS

    DatePrice TargetRatingAnalyst
    12/9/2025$136.00Equal Weight
    Barclays
    11/21/2025Sector Weight
    KeyBanc Capital Markets
    7/17/2025$155.00Outperform → Market Perform
    Leerink Partners
    6/18/2025$160.00Buy → Hold
    Stifel
    12/2/2024$215.00Outperform
    Leerink Partners
    7/25/2024$220.00Buy
    BTIG Research
    1/12/2024$195.00 → $215.00Buy
    Stifel
    12/19/2023$230.00Buy
    Jefferies
    More analyst ratings

    $ZTS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on Zoetis with a new price target

    Barclays initiated coverage of Zoetis with a rating of Equal Weight and set a new price target of $136.00

    12/9/25 8:55:22 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    KeyBanc Capital Markets initiated coverage on Zoetis

    KeyBanc Capital Markets initiated coverage of Zoetis with a rating of Sector Weight

    11/21/25 8:12:07 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zoetis downgraded by Leerink Partners with a new price target

    Leerink Partners downgraded Zoetis from Outperform to Market Perform and set a new price target of $155.00

    7/17/25 8:01:13 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZTS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Zoetis Declares First Quarter 2026 Dividend; Board Approves 6% Payment Increase

    The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.53 per share for the first quarter of 2026, an increase of 6% from the quarterly dividend rate paid in 2025. The dividend will be paid on Tuesday, March 3, 2026, to all holders of record of the Company's common stock as of the close of business on Tuesday, January 20, 2026. About Zoetis As the world's leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide --

    12/11/25 4:15:00 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zoetis Receives Health Canada Approval for Portela™(relfovetmab injection) to Alleviate Pain Associated with Osteoarthritis in Cats

    Zoetis Inc. today announced that Health Canada has approved Portela™ (relfovetmab injection) for the alleviation of pain associated with osteoarthritis (OA) in cats. Designed to provide three months of OA pain relief with a single injection, Portela targets anti-nerve growth factor (NGF), which is a key mediator of OA pain and inflammation. In a nine-month field trial in Europe, Portela demonstrated effectiveness in alleviating OA pain and was found to be well tolerated, including by cats identified with kidney disease at IRIS stage 1, 2 or 31. Portela is also approved in the European Union (EU), and Zoetis anticipates making Portela commercially available in Canada and the EU in 2026. "H

    12/5/25 8:30:00 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zoetis Highlights R&D Leadership and Long-Term Growth Opportunity at Innovation Webcast

    Underscores Proven Innovation Model, Robust and Diversified Pipeline with 12 Potential Blockbuster1 Candidates, and Unmatched Scale and Capabilities Animal Health Leader Positioned to Deliver Sustained Revenue Growth, Profitability and Shareholder Value Zoetis Inc. (NYSE:ZTS), the world's leading animal health company, will host an Innovation Webcast today at 8:30 a.m. ET to provide an update on its proven innovation model, robust and diversified R&D pipeline, and upcoming growth catalysts as the company continues pioneering the future of animal health. "The pace of animal health innovation is accelerating alongside a growing appreciation for the essential role animals play in our lives

    12/2/25 7:30:00 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZTS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by Zoetis Inc.

    3 - Zoetis Inc. (0001555280) (Issuer)

    12/2/25 4:28:48 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Tilenius Stephanie

    4 - Zoetis Inc. (0001555280) (Issuer)

    12/2/25 4:28:43 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Executive Vice President Fuller Julie

    4 - Zoetis Inc. (0001555280) (Issuer)

    10/14/25 4:27:52 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZTS
    SEC Filings

    View All

    Zoetis Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Zoetis Inc. (0001555280) (Filer)

    12/11/25 4:17:25 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zoetis Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Zoetis Inc. (0001555280) (Filer)

    12/2/25 8:00:17 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Zoetis Inc.

    10-Q - Zoetis Inc. (0001555280) (Filer)

    11/4/25 3:02:59 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZTS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    January 13, 2022 - FDA Approves Novel Treatment to Control Pain in Cats with Osteoarthritis, First Monoclonal Antibody Drug for Use in Any Animal Species

    For Immediate Release: January 13, 2022 Today, the U.S. Food and Drug Administration approved Solensia (frunevetmab injection), the first treatment for the control of pain associated with osteoarthritis in cats and the first monoclonal antibody (mAb) new animal drug approved by the FDA for use in any animal species.  Frunevetmab, the active ingredient in Solensia, is a cat-specific monoclonal antibody (a type o

    1/13/22 10:26:13 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZTS
    Leadership Updates

    Live Leadership Updates

    View All

    Zoetis Announces Retirement of Rob Polzer at the End of 2025 and the Appointment of Kevin Esch as President of Research & Development for World Leader in Animal Health Beginning in 2026

    Dr. Rob Polzer to Retire at the End of the Year After 10-Year Distinguished Career of Advancing Veterinary Medicine and Innovation Zoetis Inc. (NYSE:ZTS) today announced that following a 10-year distinguished career dedicated to advancing veterinary medicine and innovation, Rob Polzer, Ph.D., Executive Vice President and President, Research and Development, has made the personal decision to retire at the end of 2025. After a planful succession process, Zoetis has appointed Kevin Esch, D.V.M, M.P.H., Ph.D., Dipl. ACVP (anatomic) to succeed Dr. Polzer in this role, effective January 1, 2026. Dr. Esch currently serves as Senior Vice President of Global Therapeutics at Zoetis and joined Zoe

    11/3/25 4:15:00 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zoetis Appoints Stephanie Tilenius to its Board of Directors

    Health entrepreneur brings her digital and artificial intelligence (AI) experience to Zoetis Board Zoetis Inc. (NYSE:ZTS) today announced the appointment of Stephanie Tilenius to its Board of Directors, effective as of December 1, 2025. Ms. Tilenius brings extensive experience in technology-forward, digital health organizations to the Zoetis Board. Ms. Tilenius is a serial entrepreneur and has founded several healthcare companies, including most recently a stealth company in the longevity AI space. Previously, she founded Vida Health, Inc., a leading B2B chronic care platform focusing on diabetes and obesity, and scaled it nationally for Fortune 500 companies, large payers and healthcar

    10/28/25 8:30:00 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dr. Mark Stetter Elected to Zoetis Board of Directors

    Dean of the University of California, Davis School of Veterinary Medicine brings extensive and valuable experience in animal health to Zoetis Board Zoetis Inc. (NYSE:ZTS) today announced the election of Dr. Mark Stetter to its Board of Directors, effective as of the company's annual shareholder meeting on May 21, 2025. Dr. Stetter brings extensive experience in veterinary medicine and animal health, including as Dean of the University of California, Davis School of Veterinary Medicine, to the Zoetis Board. His career in animal health includes pets, livestock, exotic animals, research and wildlife. He will serve on the Board's Quality and Innovation Committee. "Dr. Stetter brings invaluab

    5/22/25 4:15:00 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZTS
    Financials

    Live finance-specific insights

    View All

    Zoetis Declares First Quarter 2026 Dividend; Board Approves 6% Payment Increase

    The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.53 per share for the first quarter of 2026, an increase of 6% from the quarterly dividend rate paid in 2025. The dividend will be paid on Tuesday, March 3, 2026, to all holders of record of the Company's common stock as of the close of business on Tuesday, January 20, 2026. About Zoetis As the world's leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide --

    12/11/25 4:15:00 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zoetis Highlights R&D Leadership and Long-Term Growth Opportunity at Innovation Webcast

    Underscores Proven Innovation Model, Robust and Diversified Pipeline with 12 Potential Blockbuster1 Candidates, and Unmatched Scale and Capabilities Animal Health Leader Positioned to Deliver Sustained Revenue Growth, Profitability and Shareholder Value Zoetis Inc. (NYSE:ZTS), the world's leading animal health company, will host an Innovation Webcast today at 8:30 a.m. ET to provide an update on its proven innovation model, robust and diversified R&D pipeline, and upcoming growth catalysts as the company continues pioneering the future of animal health. "The pace of animal health innovation is accelerating alongside a growing appreciation for the essential role animals play in our lives

    12/2/25 7:30:00 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zoetis Announces Third Quarter 2025 Results

    Reports Revenue of $2.4 Billion, Growing 1%, and Net Income of $721 Million, or $1.63 per Diluted Share, Increasing 6% and 9%, Respectively, on a Reported Basis for Third Quarter 2025 Delivers 4% Organic Operational Growth in Revenue and 9% Organic Operational Growth in Adjusted Net Income for Third Quarter 2025 Reports Adjusted Net Income of $754 Million, or Adjusted Diluted EPS of $1.70, for Third Quarter 2025 Revises Full Year 2025 Revenue Guidance to $9.400 - $9.475 Billion with Organic Operational Revenue Growth of 5.5% to 6.5% Based on Broader Macro Trends and the Operational Environment Narrows Full Year 2025 Guidance for Organic Operational Growth in Adjusted Net Income

    11/4/25 7:00:00 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZTS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Zoetis Inc. (Amendment)

    SC 13G/A - Zoetis Inc. (0001555280) (Subject)

    2/13/24 5:17:36 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Zoetis Inc. (Amendment)

    SC 13G/A - Zoetis Inc. (0001555280) (Subject)

    1/26/24 11:49:41 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Zoetis Inc. (Amendment)

    SC 13G/A - Zoetis Inc. (0001555280) (Subject)

    2/9/23 11:37:19 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care